These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 38323500)

  • 21. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.
    Thyssen JP; Yosipovitch G; Paul C; Kwatra SG; Chu CY; DiBonaventura M; Feeney C; Zhang F; Myers D; Rojo R; Valdez H
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):434-443. PubMed ID: 34779063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.
    Schmid-Grendelmeier P; Gooderham MJ; Hartmann K; Konstantinou GN; Fellmann M; Koulias C; Clibborn C; Biswas P; Brunner PM
    Allergy; 2024 Jan; 79(1):174-183. PubMed ID: 37988255
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registry.
    Kamphuis E; Boesjes CM; Loman L; Bakker DS; Poelhekken M; Zuithoff NPA; Kamsteeg M; Romeijn GLE; van Wijk F; de Bruin-Weller MS; de Graaf M; Schuttelaar MLA
    Pediatr Allergy Immunol; 2022 Dec; 33(12):e13887. PubMed ID: 36564878
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis.
    Silverberg JI; Thyssen JP; Fahrbach K; Mickle K; Cappelleri JC; Romero W; Cameron MC; Myers DE; Clibborn C; DiBonaventura M
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1797-1810. PubMed ID: 33991374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.
    Boesjes CM; Kamphuis E; de Graaf M; Spekhorst LS; Haeck I; van der Gang LF; Loman L; Zuithoff NPA; Dekkers C; van der Rijst LP; Romeijn GLE; Oosting AJ; Gostynksi A; van Lynden-van Nes AMT; Tupker RA; van Tuyll van Serooskerken AM; Flinterman A; Politiek K; Touwslager WRH; Christoffers WA; Stewart SM; Kamsteeg M; Schuttelaar MA; de Bruin-Weller MS
    JAMA Dermatol; 2024 Oct; 160(10):1044-1055. PubMed ID: 39110432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
    Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
    Boesjes CM; Kamphuis E; Zuithoff NPA; Bakker DS; Loman L; Spekhorst LS; Haeck I; Kamsteeg M; Van Lynden-van Nes AMT; Garritsen FM; Politiek K; Oldhoff M; De Graaf M; Schuttelaar MLA; De Bruin-Weller MS
    Acta Derm Venereol; 2022 Nov; 102():adv00820. PubMed ID: 36420885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation.
    Chiricozzi A; Ortoncelli M; Schena D; Gori N; Ferrucci SM; Babino G; Napolitano M; Fargnoli MC; Stingeni L; Rossi M; Romanelli M; Balestri R; Pellegrino M; Parodi A; Bertoldi AM; Palazzo G; Antonelli F; Pitino A; Tripepi G; Fabbrocini G; Balato A; Marzano AV; Girolomoni G; Ribero S; Peris K
    Am J Clin Dermatol; 2023 Nov; 24(6):953-961. PubMed ID: 37322324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
    Napolitano M; Ferrucci SM; Foggia L; Hansel K; Pezzolo E; Stingeni L; Antonelli E; Picone V; Patruno C
    Clin Drug Investig; 2024 Jan; 44(1):71-77. PubMed ID: 38105393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abrocitinib efficacy and safety in moderate-to-severe atopic dermatitis by race, ethnicity, and Fitzpatrick skin type.
    Alexis AF; Silverberg JI; Rice ZP; Armstrong AW; Desai SR; Fonacier L; Kabashima K; Biswas P; Cella RR; Chan GL; Levenberg M
    Ann Allergy Asthma Immunol; 2024 Mar; 132(3):383-389.e3. PubMed ID: 37949351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
    Reich K; Lio PA; Bissonnette R; Alexis AF; Lebwohl MG; Pink AE; Kabashima K; Boguniewicz M; Nowicki RJ; Valdez H; Zhang F; DiBonaventura M; Cameron MC; Clibborn C
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3228-3237.e2. PubMed ID: 36108923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis.
    Drucker AM; Morra DE; Prieto-Merino D; Ellis AG; Yiu ZZN; Rochwerg B; Di Giorgio S; Arents BWM; Burton T; Spuls PI; Schmitt J; Flohr C
    JAMA Dermatol; 2022 May; 158(5):523-532. PubMed ID: 35293977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of abrocitinib for the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized clinical trials.
    Meher BR; Mohanty RR; Padhy BM
    J Dermatolog Treat; 2022 Jun; 33(4):2335-2343. PubMed ID: 34315323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness of abrocitinib treatment in patients with difficult-to-treat atopic dermatitis.
    Olydam JI; Schlösser AR; Custurone P; Nijsten TEC; Hijnen D
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2537-2542. PubMed ID: 37478296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis.
    Armstrong AW; Alexis AF; Blauvelt A; Silverberg JI; Feeney C; Levenberg M; Chan G; Zhang F; Fostvedt L
    Dermatol Ther (Heidelb); 2024 Jul; 14(7):1849-1861. PubMed ID: 38896380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial.
    Blauvelt A; Silverberg JI; Lynde CW; Bieber T; Eisman S; Zdybski J; Gubelin W; Simpson EL; Valenzuela F; Criado PR; Lebwohl MG; Feeney C; Khan T; Biswas P; DiBonaventura M; Valdez H; Cameron MC; Rojo R
    J Am Acad Dermatol; 2022 Jan; 86(1):104-112. PubMed ID: 34416294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib.
    Simpson EL; Wollenberg A; Bissonnette R; Silverberg JI; Papacharalambous J; Zhu L; Zhang W; Beebe JS; Vincent M; Peeva E; Bushmakin AG; Cappelleri JC; Chen L; Sikirica V; Xenakis J
    Dermatitis; 2021 Oct; 32(1S):S53-S61. PubMed ID: 33795561
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan.
    Hagino T; Hamada R; Yoshida M; Saeki H; Fujimoto E; Kanda N
    Clin Drug Investig; 2024 Apr; 44(4):261-269. PubMed ID: 38446396
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.